评估数字乳腺断层合成对早期癌症检出的影响:来自连续筛查的见解
基于前瞻性马尔默乳腺断层合成筛查试验(MBTST)的二次分析,纳入14848名参与者,比较DBT筛查与后续连续两轮数字乳腺X线摄影(DM1、DM2)的癌症检出率。DBT筛查癌症检出率高于后续DM1和DM2,后续DM1的浸润性癌比例低于MBTST,DM1中Luminal A样癌 odds 低于MBTST,提示DBT筛查通过增加Luminal A样癌检出实现更早发现。
要点
- DBT筛查癌症检出率为8.7/1000女性,高于后续DM1的4.6/1000和DM2的5.3/1000。
- MBTST中浸润性癌比例为84.9%,DM1为66%,DM2为83%。
- DM1中Luminal A样癌 odds 为0.28(95%CI 0.12,0.66),低于MBTST。
核心结论
- DBT筛查后DM1的癌症检出率和浸润性癌比例较低,DM2则升高,提示DBT筛查主要因增加Luminal A样癌检出而实现更早发现癌症。
研究设计与样本
- 前瞻性配对马尔默乳腺断层合成筛查试验(MBTST)的二次分析,2010年1月至2015年2月进行,参与女性在一次筛查中接受单视图DBT和双视图DM,随后随访第一轮(DM1)和第二轮(DM2)连续双视图DM筛查;最终参与者14848名(中位年龄57岁,IQR 49-65岁),DM1筛查12876名(中位年龄58岁,IQR 50-66岁),DM2筛查10883名(中位年龄59岁,IQR 51-67岁);癌症诊断通过查阅记录确认;使用调整年龄的logistic回归模型,以MBTST为参考计算Luminal A样癌的odds。
诊断标准与关键数值
- MBTST中DBT筛查癌症检出率为8.7/1000女性(95%CI 7.3,10.3),DM筛查为6.5/1000女性(95%CI 5.2,7.9)。
- DM1癌症检出率为4.6/1000女性(95%CI 3.6,5.9),DM2为5.3/1000女性(95%CI 4.1,6.9)。
- MBTST浸润性癌比例为84.9%(118/139例癌症),DM1为66%(39/59例癌症),DM2为83%(50/60例癌症)。
- 以MBTST为参考,DM1中Luminal A样癌 odds 为0.28(95%CI 0.12,0.66,P=.004),DM2为0.80(95%CI 0.40,1.58,P=.52)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Analysis of how digital breast tomosynthesis (DBT) screening affects consecutive screening performance is important to estimate its future value in screening. Purpose To evaluate whether DBT contributes to early detection of breast cancer by assessing cancer detection rates (CDRs), including the fraction of invasive cancers and cancer subtypes in consecutive routine digital mammography (DM). Materials and Methods The paired prospective Malmö Breast Tomosynthesis Screening Trial (MBTST) was performed between January 2010 and February 2015. Participating women underwent one-view DBT and two-view DM at one screening occasion. In this secondary analysis, women were followed up through their first (DM1) and second (DM2) consecutive two-view DM screening rounds after MBTST participation. Cancer diagnoses were identified by referencing records. A logistic regression model, adjusted for age, was used to calculate the odds of luminal A-like cancers with use of the MBTST as reference. Results There were 14 848 final participants in the MBTST (median age, 57 years [IQR, 49-65 years]). Of those, 12 876 women were screened in DM1 (median age, 58 years [IQR, 50-66 years]) and 10 883 were screened in DM2 (median age, 59 years [IQR, 51-67 years]). Compared with CDRs in the trial of 6.5 of 1000 women (95% CI: 5.2, 7.9) for DM and 8.7 of 1000 women (95% CI: 7.3, 10.3) for DBT, the CDR was lower in DM1 (4.6 of 1000 women [95% CI: 3.6, 5.9]) and DM2 (5.3 of 1000 women [95% CI: 4.1, 6.9]). The proportion of invasive cancers was 84.9% (118 of 139 cancers) in the MBTST; the corresponding numbers were 66% (39 of 59 cancers) for DM1 and 83% (50 of 60 cancers) for DM2. The odds of luminal A-like cancers were lower in DM1 at 0.28 (95% CI: 0.12, 0.66 [P = .004]) but not in DM2 at 0.80 (95% CI: 0.40, 1.58 [P = .52]) versus screening in the MBTST. Conclusion CDR and the fraction of invasive cancers were lower in DM1 and then increased in DM2 following the MBTST, indicating earlier cancer detection mainly due to increased detection of luminal A-like cancers in DBT screening. Clinical trials registration no. NCT01091545 © RSNA, 2024 See also the editorial by Hooley and Philpotts in this issue.
引用
- Jögi A, Johnson K, Wittgren S, et al. Assessing Digital Breast Tomosynthesis Impact on Early Cancer Detection: Insights from Consecutive Screening. Radiology. 2024. PMID: 39078298. doi:10.1148/radiol.233417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。